var data={"title":"Dopamine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dopamine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6069?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dopamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dopamine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dopamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dopamine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708685\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Antidote for peripheral ischemia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">To prevent sloughing and necrosis in ischemic areas, the area should be infiltrated as soon as possible with 10 to 15 mL of sodium chloride 0.9% injection containing phentolamine 5 to 10 mg, an adrenergic blocking agent. Pediatric dosage of phentolamine should be 0.1 to 0.2 mg/kg up to a maximum of 10 mg per dose. A syringe with a fine hypodermic needle should be used, and the solution liberally infiltrated throughout the ischemic area. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. Therefore, phentolamine should be given as soon as possible after the extravasation is noted.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162703\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Adrenergic Agonist Agent;</li>\n      <li>\n        Inotrope</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162660\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemodynamic support:</b> IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> Dosage range: 2 to 20 mcg/kg/minute; titrate to desired response (maximum: 50 mcg/kg/minute; however, doses &gt;20 mcg/kg/minute may not have a beneficial effect on blood pressure and may increase the risk of tachyarrhythmias); infusion may be gradually increased by 5 to 10 mcg/kg/minute increments until optimal response is obtained</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cardiogenic shock (off-label dose):</i> IV: 0.5 to 20 mcg/kg/minute (AHA [van Diepen 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Inotropic support in advanced heart failure:</i> IV infusion: 5 to 15 mcg/kg/minute; lower doses are preferred (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>ACLS guideline recommendations (to treat hypotension especially if associated with symptomatic bradycardia in the immediate post-cardiac arrest care setting) (off-label use):</i> Initial: 5 to 10 mcg/kg/minute; titrate to effect (AHA [Peberdy 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If dosages &gt;20 to 30 mcg/kg/minute are needed, a more direct-acting vasopressor may be more beneficial (ie, epinephrine, norepinephrine).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hemodynamic effects of dopamine are dose dependent (however, this is relative and there is overlap of clinical effects between dosing ranges): </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Low-dose: 1 to 5 mcg/kg/minute, results in increased renal blood flow and urine output. <b>Note: </b>The use of low-dose dopamine to prevent or treat acute kidney injury is not recommended (KDIGO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermediate-dose: 5 to 10 mcg/kg/minute, results in increased renal blood flow, heart rate, cardiac contractility, and cardiac output</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High-dose: &gt;10 mcg/kg/minute, alpha-adrenergic effects begin to predominate, resulting in vasoconstriction, increased blood pressure, in addition to increased heart rate, cardiac contractility, and cardiac output due to beta-adrenergic effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162681\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dopamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dopamine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemodynamic support:</b> Infants, Children, and Adolescents: IV infusion: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediatric Advanced Life Support (PALS) </i>\n      <i>guideline recommendation (to maintain cardiac output and for postresuscitation stabilization) (off-label use):</i> IV or Intraosseous infusion: Dose range: 2 to 20 mcg/kg/minute; titrate gradually by 5- to 10-mcg/kg/minute increments until optimal response is obtained (AHA [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Hemodynamic effects of dopamine are dose dependent (however, this is relative and there is overlap of clinical effects between dosing ranges): </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Low-dose: 1 to 5 mcg/kg/minute, results in increased renal blood flow and urine output. <b>Note: </b>The use of low-dose dopamine to prevent or treat acute kidney injury is not recommended (KDIGO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermediate-dose: 5 to 10 mcg/kg/minute, results in increased renal blood flow, heart rate, cardiac contractility, and cardiac output</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High-dose: &gt;10 mcg/kg/minute, alpha-adrenergic effects begin to predominate, resulting in vasoconstriction, increased blood pressure in addition to increased heart rate, cardiac contractility, and cardiac output due to beta-adrenergic effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162661\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162636\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.8 mg/mL (250 mL, 500 mL); 1.6 mg/mL (250 mL, 500 mL); 3.2 mg/mL (250 mL); 40 mg/mL (5 mL, 10 mL); 80 mg/mL (5 mL); 160 mg/mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162622\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162640\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer as a continuous infusion with the use of an infusion pump. Administer into large vein to prevent the possibility of extravasation (central line administration); monitor continuously for free flow; use infusion device to control rate of flow; administration into an umbilical arterial catheter is not recommended; when discontinuing the infusion, gradually decrease the dose of dopamine (sudden discontinuation may cause hypotension). Vials (concentrated solution) must be diluted prior to use.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative) antidote. Apply dry warm compresses (Hurst 2004; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Phentolamine:</i> Dilute 5 to 10 mg in 10 to 20 mL NS and administer into extravasation site as soon as possible after extravasation; may readminister if patient remains symptomatic (Reynolds 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternatives to phentolamine:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nitroglycerin topical 2% ointment (based on limited data):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adults:</i> Apply a 1-inch strip to the site of ischemia; may repeat every 8 hours as necessary (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pediatrics:</i> Apply 4 mm/kg as a thin ribbon to the site of ischemia; may repeat after 8 hours if needed (Wong 1992) <b>or</b> apply a 1-inch strip to the site of ischemia; may repeat every 8 hours as necessary (Denkler 1989; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Terbutaline (based on limited case reports): Infiltrate extravasation area using a solution of terbutaline 1 mg diluted in 10 mL NS (large extravasation site; administration volume varied from 3 to 10 mL) <b>or</b> 1 mg diluted in 1 mL NS (small/distal extravasation site; administration volume varied from 0.5 to 1 mL) (Reynolds 2014; Stier 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471801\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 400 mg in 250 mL (concentration: 1600 <b>mcg</b>/mL) <b>or</b> 800 mg in 250 mL (concentration: 3200 <b>mcg</b>/mL)  of D<sub>5</sub>W or NS </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471802\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 1600 <b>mcg</b>/mL <b>or</b> 3200 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162639\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hemodynamic support:</b> Adjunct in the treatment of shock (eg, MI, open heart surgery, renal failure, cardiac decompensation) that persists after adequate fluid volume replacement when indicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>\n        <b>Guideline recommendations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiogenic shock:</i> To maintain systemic perfusion and preserve end-organ performance in patients with cardiogenic shock. Vasopressor therapy is indicated in patients with hemodynamic instability (eg, systolic blood pressure &lt;90 mm Hg or evidence of end organ hypoperfusion) or the following etiologies of cardiogenic shock: Right ventricular failure, aortic regurgitation, mitral regurgitation, ventricular septal defect after MI, or bradycardia. <b>Note:</b> Norepinephrine is preferred over dopamine for most of these etiologies of cardiogenic shock due to lower likelihood for causing arrhythmias. However, in the case of shock due to bradycardia or aortic regurgitation, then dopamine is preferred (ACCF/AHA [Yancy 2013], AHA [van Diepen 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inotropic support in advanced heart failure:</i> Bridge therapy in stage D HF unresponsive to guideline-directed medical therapy and device therapy in patients awaiting heart transplant or mechanical circulatory support; short-term management of hospitalized patients with severe systolic dysfunction presenting with low blood pressure and significantly depressed cardiac output; long-term management (palliative therapy) in select patients with stage D heart failure unresponsive to guideline-directed medical therapy and device therapy who are not candidates for heart transplant or mechanical circulatory support (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sepsis and septic shock:</i> Suggested for use as an alternative vasopressor to norepinephrine <b>only</b> in highly selected patients (eg, patients with low risk of tachyarrhythmias and absolute or relative bradycardia) (SCCM [Rhodes 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725326\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Heart block unresponsive to atropine or pacing; Symptomatic bradycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162712\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">DOPamine may be confused with DOBUTamine, Dopram</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162628\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Angina pectoris, atrial fibrillation, bradycardia, ectopic beats, hypertension, hypotension, palpitations, tachycardia, vasoconstriction, ventricular arrhythmia, ventricular conduction, widened QRS complex on ECG</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Gangrene (high dose), piloerection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Increased serum glucose (usually not above normal limits)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Azotemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Increased intraocular pressure, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Tissue necrosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162643\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sulfites (commercial preparation contains sodium bisulfite); pheochromocytoma; uncorrected tachyarrhythmias; ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162626\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: May cause increases in heart rate, increasing the risk of tachycardia and other tachyarrhythmias including ventricular arrhythmias (Tisdale 1995). In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death (Young 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; infuse into a large vein if possible. Avoid infusion into leg veins. Watch IV site closely. <b>[US Boxed Warning]: If extravasation occurs, infiltrate the area with diluted phentolamine (5 to 10 mg in 10 to 15 mL of saline) with a fine hypodermic needle. Phentolamine should be administered as soon as possible after extravasation is noted to prevent sloughing/necrosis.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, cardiac arrhythmias and/or occlusive vascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Active myocardial ischemia/post-myocardial infarction: Use with caution in patients with active myocardial ischemia or recent myocardial infarction; may increase myocardial oxygen consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias (ACC/AHA/ESC [Zipes 2006]; Tisdale 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Shock: The use of dopamine in adult patients with shock (majority of patients had septic shock) demonstrated a higher incidence of adverse events (eg, tachyarrhythmias) (De Backer 2010). Higher 28-day mortality was also seen in patients with septic shock with the use of dopamine as compared to norepinephrine (De Backer 2012; Vasu 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO inhibitors; prolong hypertension may result from concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium metabisulfite: Product may contain sodium metabisulfite.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Assure adequate circulatory volume to minimize need for vasoconstrictors when used in hemodynamic support. Avoid hypertension; monitor blood pressure closely and adjust infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term therapy: According to the ACCF/AHA 2013 heart failure guidelines, long-term use of intravenous inotropic therapy without a specific indication or for reasons other than palliation is potentially harmful (ACCF/AHA [Yancy 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299227\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of COMT, OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162630\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9384&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">COMT Inhibitors: May decrease the metabolism of COMT Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of DOPamine. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine.  Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the arrhythmogenic effect of DOPamine. Management: Avoid use of dopamine in patients receiving halogenated hydrocarbon anesthetics.  If concomitant treatment cannot be avoided, monitor for arrhythmia.  Dopamine induced ventricular arrhythmia may be reversible with propranolol based on animal data.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: DOPamine may enhance the hypotensive effect of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of DOPamine. Management: Initiate dopamine at no greater than one-tenth (1/10) of the usual dose in patients who are taking (or have taken within the last 2 to 3 weeks) monoamine oxidase inhibitors. Monitor for an exaggerated hypertensive response to dopamine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Management: Avoid, if possible, the use of direct-acting alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162632\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13314046\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. It is not known if dopamine crosses the placenta. Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Appropriate medications should not be withheld due to concerns of fetal teratogenicity. Dopamine use during the post-resuscitation phase may be considered; however, the effects of vasoactive medications on the fetus should also be considered. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20306045\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dopamine is present in breast milk. The manufacturer recommends that caution be exercised when administering dopamine to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162634\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, ECG, heart rate, CVP, RAP, MAP; serum glucose, renal function; urine output; if pulmonary artery catheter is in place, monitor CI, PCWP, SVR, and PVR</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162625\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates both adrenergic and dopaminergic receptors, lower doses are mainly dopaminergic stimulating and produce renal and mesenteric vasodilation, higher doses also are both dopaminergic and beta<sub>1</sub>-adrenergic stimulating and produce cardiac stimulation and renal vasodilation; large doses stimulate alpha-adrenergic receptors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162642\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note: </b>Children: Dopamine has exhibited nonlinear kinetics in children; with dose changes, may not achieve steady-state for ~1 hour rather than 20 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Adults: Within 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Adults: &lt;10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Renal, hepatic, plasma; 75% to inactive metabolites by monoamine oxidase and 25% to norepinephrine (active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~2 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as metabolites) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Neonates: Varies and appears to be age related; clearance is more prolonged with combined hepatic and renal dysfunction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323119\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DOPamine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (5 mL): $3.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/mL (5 mL): $3.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg/mL (5 mL): $7.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DOPamine in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg/mL 5% (250 mL): $11.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.6 mg/mL 5% (250 mL): $15.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.2 mg/mL 5% (250 mL): $23.19</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162646\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A Si Ke Ding (CN);</li>\n      <li>Admeda (HU);</li>\n      <li>Bagotropin (UY);</li>\n      <li>Cardiofast (PH);</li>\n      <li>Cardopa (BD);</li>\n      <li>Catabon (JP);</li>\n      <li>Cetadop (ID);</li>\n      <li>Cordodopa Forte (PT);</li>\n      <li>Domin (IN);</li>\n      <li>Dopabane (BR);</li>\n      <li>Dopacard (IN);</li>\n      <li>Dopacin (TZ);</li>\n      <li>Dopacris (BR);</li>\n      <li>Dopamax (PH);</li>\n      <li>Dopamex (TH);</li>\n      <li>Dopamin (BG, CH, DE, NO);</li>\n      <li>Dopamin AWD (HN);</li>\n      <li>Dopamin Giulini (HU, LU);</li>\n      <li>Dopamina (ES);</li>\n      <li>Dopamine (FR);</li>\n      <li>Dopamine Injection (AU);</li>\n      <li>Dopamine Pierre Fabre (LU);</li>\n      <li>Dopaminex (BD);</li>\n      <li>Dopaminum (PL);</li>\n      <li>Dopamix (KR);</li>\n      <li>Dopar (IN, TW);</li>\n      <li>Dopasin (KR);</li>\n      <li>Dopasol (LK);</li>\n      <li>Dopatropin (AR);</li>\n      <li>Dopavate (TW);</li>\n      <li>Dopina (VE);</li>\n      <li>Dopinga (IN);</li>\n      <li>Dopmin (DK, EE, FI, MY, RU, TR, TW, UA);</li>\n      <li>Dopnax (PH);</li>\n      <li>Dopress (IN);</li>\n      <li>Dopuramin (KR);</li>\n      <li>Drinalken (MX);</li>\n      <li>Dynatra (LU, NL);</li>\n      <li>Emodopan (PE);</li>\n      <li>Giludop (AT, GR, SE, TR);</li>\n      <li>Glomin (ID);</li>\n      <li>Inopan (VN);</li>\n      <li>Inopin (TH);</li>\n      <li>Inotropisa (CO);</li>\n      <li>Inovan (JP);</li>\n      <li>Intropin (IE, PK);</li>\n      <li>Intropin IV (MY);</li>\n      <li>Limdopa (VN);</li>\n      <li>Medopa (MT, PT);</li>\n      <li>Megadose (AR, UY);</li>\n      <li>Myocard (PH);</li>\n      <li>Myotil (HK, QA);</li>\n      <li>Pamin (BD);</li>\n      <li>Pre Dopa (JP);</li>\n      <li>Proinfark (ID);</li>\n      <li>Revivan (IT);</li>\n      <li>Tensamin (CZ, SK);</li>\n      <li>Tropin (KR, PK, SG);</li>\n      <li>Udopa (KR);</li>\n      <li>Uramin (TW);</li>\n      <li>Zetarina (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15942351\"></a>Argalious M, Motta P, Khandwala F, et al. &quot;Renal dose&quot; dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery [published corrction appears in: <i>Crit Care Med</i>. 2005;33(7):1678.]. <i>Crit Care Med</i>. 2005;33(6):1327-1332.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/15942351/pubmed\" target=\"_blank\" id=\"15942351\">15942351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11191541\"></a>Bellomo R, Chapman M, Finfer S, et al, &ldquo;Low-dose Dopamine in Patients With Early Renal Dysfunction: A Placebo-Controlled Randomised Trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group,&rdquo; <i>Lancet</i>, 2000, 356(9248):2139-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/11191541/pubmed\" target=\"_blank\" id=\"11191541\">11191541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo; <i>Crit Care Med</i>, 2009, 37(2):666-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan TY, &ldquo;Low-Dose Dopamine in Severe Right Heart Failure and Chronic Obstructive Pulmonary Disease,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(5):493-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/7655133/pubmed\" target=\"_blank\" id=\"7655133\">7655133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24247300\"></a>Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA</i>. 2013;310(23):2533-2543.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/24247300/pubmed\" target=\"_blank\" id=\"24247300\">24247300</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Backer D, Aldecoa C, Njimi H, et al, &ldquo;Dopamine versus Norepinephrine in the Treatment of Septic Shock: A Meta-Analysis,&rdquo; <i>Crit Care Med</i>, 2012, 40(3):725-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/22036860/pubmed\" target=\"_blank\" id=\"22036860\">22036860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Backer D, Biston P, Devriendt J, et al, &ldquo;Comparison of Dopamine and Norepinephrine in the Treatment of Shock,&rdquo; <i>N Engl J Med</i>, 2010, 362(9):779-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20200382/pubmed\" target=\"_blank\" id=\"20200382\">20200382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denkler KA and Cohen BE, &ldquo;Reversal of Dopamine Extravasation Injury With Topical Nitroglycerin Ointment,&rdquo; <i>Plast Reconstr Surg</i>, 1989, 84(5):811-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/2510208/pubmed\" target=\"_blank\" id=\"2510208\">2510208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopamine Hydrochloride Injection (Fliptop, Pintop, LifeShield Fliptop Vials) [prescribing information]. Lake Forest, IL: Hospira; October 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopamine Hydrochloride in 5% Dextrose Injection [prescribing information]. Irvine, CA: B. Braun: November 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopamine Hydrochloride in 5% Dextrose Injection [prescribing information]. Lake Forest, IL: Hospira; April 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action. <i>Circulation</i>. 2008;117(2):200-205. <i>J Card Fail</i>. 2010;16(12):922-930.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/18172028/pubmed\" target=\"_blank\" id=\"18172028\">18172028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15809463\"></a>Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. <i>Ann Intern Med</i>. 2005;142(7):510-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/15809463/pubmed\" target=\"_blank\" id=\"15809463\">15809463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo; <i>Crit Care Med</i>, 2004, 32(9):1928-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/15343024/pubmed\" target=\"_blank\" id=\"15343024\">15343024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S and McMillan M, &ldquo;Innovative Solutions in Critical Care Units: Extravasation Guidelines,&rdquo; <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson RL Jr, &ldquo;Low-Dose Dopamine and Oxygen Transport by the Lung,&rdquo; <i>Circulation</i>, 1998, 98(2):97-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/9679713/pubmed\" target=\"_blank\" id=\"9679713\">9679713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012;2(suppl 1):1-138. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kellum JA and Decker J, &ldquo;Use of Dopamine in Acute Renal Failure: A Meta-Analysis,&rdquo; <i>Crit Care Med</i>, 2001, 29(8):1526-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/11505120/pubmed\" target=\"_blank\" id=\"11505120\">11505120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S876-S908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin C, Papazian L, Perrin G, et al, &ldquo;Norepinephrine or Dopamine for the Treatment of Hyperdynamic Septic Shock?&rdquo; <i>Chest</i>, 1993, 103(6):1826-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/8404107/pubmed\" target=\"_blank\" id=\"8404107\">8404107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S729-S767.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel GP, Grahe JS, Sperry M, et al, &ldquo;Efficacy and Safety of Dopamine versus Norepinephrine in the Management of Septic Shock,&rdquo; <i>Shock</i>, 2010, 33(4):375-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/19851126/pubmed\" target=\"_blank\" id=\"19851126\">19851126</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar RW, et al, &ldquo;Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):768-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956225/pubmed\" target=\"_blank\" id=\"20956225\">20956225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28101605\"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sakr Y, Reinhart K, Vincent JL, et al, &ldquo;Does Dopamine Administration in Shock Influence Outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study,&rdquo; <i>Crit Care Med</i>, 2006, 34(3):589-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/16505643/pubmed\" target=\"_blank\" id=\"16505643\">16505643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stier PA, Bogner MP, Webster K, et al, &quot;Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia,&quot; <i>Am J Emerg Med</i>, 1999, 17(1):91-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/9928712/pubmed\" target=\"_blank\" id=\"9928712\">9928712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. <i>Prog Cardiovasc Dis</i>. 1995;38(2):167-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/7568905/pubmed\" target=\"_blank\" id=\"7568905\">7568905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24485633\"></a>Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. <i>Int J Cardiol</i>. 2014;172(1):115-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/24485633/pubmed\" target=\"_blank\" id=\"24485633\">24485633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van de Borne P, Oren R, and Somers VK, &ldquo;Dopamine Depresses Minute Ventilation in Patients With Heart Failure,&rdquo; <i>Circulation</i>, 1998, 98(2):126-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/9679718/pubmed\" target=\"_blank\" id=\"9679718\">9679718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/28923988/pubmed\" target=\"_blank\" id=\"28923988\">28923988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S836.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasu TS, Cavallazzi R, Hirani A, et al, &ldquo;Norepinephrine or Dopamine for Septic Shock: Systematic Review of Randomized Clinical Trials,&rdquo; <i>J Intensive Care Med</i>, 2012, 27(3):172-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/21436167/pubmed\" target=\"_blank\" id=\"21436167\">21436167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong AF, McCulloch LM, and Sola A, &ldquo;Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates,&rdquo; <i>J Pediatr</i>, 1992, 121(6):980-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/1447671/pubmed\" target=\"_blank\" id=\"1447671\">1447671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. <i>J Heart Lung Transplant</i>. 2000;19(8 suppl):s49-s57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/11016488/pubmed\" target=\"_blank\" id=\"11016488\">11016488</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zipes DP, Camm AJ, Borggrefe M, et al; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <i>Circulation</i>. 2006;114(10):e385-e484.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dopamine-drug-information/abstract-text/16935995/pubmed\" target=\"_blank\" id=\"16935995\">16935995</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9384 Version 149.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708685\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F162703\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F162660\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F162681\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F162661\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F162636\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F162622\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F162640\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471801\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471802\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F162639\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725326\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F162712\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162628\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F162643\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F162626\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299227\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F162630\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F162632\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13314046\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20306045\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F162634\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F162625\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F162642\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323119\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F162646\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9384|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dopamine-patient-drug-information\" class=\"drug drug_patient\">Dopamine: Patient drug information</a></li><li><a href=\"topic.htm?path=dopamine-pediatric-drug-information\" class=\"drug drug_pediatric\">Dopamine: Pediatric drug information</a></li></ul></div></div>","javascript":null}